GGrantIndex
← Search

TROGLITAZONE IN EARLY TYPE 2 DIABETES MELLITUS

$32,779M01FY2000RRNIH

University Of Chicago, Chicago IL

Investigators

Linked publications & trials

Abstract

This study is 1-year, randomized, double-blind, placebo-controlled trial to test the efficacy and safety of troglitazone 600 mg OD. Efficacy assessments will determine whether postprandial glucose and overall insulin sensitivity will be improved in patients with type 2 diabetes by initiating troglitazone therapy in the early stage of their diabetes. In 50% of the total number of patients randomized to study medication, beta-cell function will be assessed with a graded glucose infusion (GGI) preceded and followed by arginine stimulation and by FSIVGTT.

View original record on NIH RePORTER →